
Signos Secures $20M to Expand CGM Use Beyond Diabetes Into Weight Loss - MedCity News
Signos is a health technology company that focuses on using continuous glucose monitoring (CGM) technology to help individuals manage their weight. The company aims to expand the application of CGM beyond diabetes, targeting consumers interested in weight loss solutions. This funding round will support their efforts to broaden the use of CGM technology in the weight management market.
Signos Secures $20M to Expand CGM Use Beyond Diabetes Into Weight Loss MedCity News
| May 31, 2026 | Khloud | $15.0M | — | United States |
| May 31, 2026 | Weitzman Jewish Museum | $100.0M | — | United States |
| May 30, 2026 | The SmAll Market | $2.0M | Pre-seed | United States |
| May 30, 2026 | Drafted | $16.0M | Seed | United States |